Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo-Progression in Metastatic Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy

NCT02019576 is registered in ClinicalTrials.gov with Sunnybrook Health Sciences Centre as lead sponsor.

NCT NCT02019576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02019576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo-Progression in Metastatic Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy
Lead sponsor
Sunnybrook Health Sciences Centre
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2014
Completion date
March 4, 2021
Enrollment
38 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell metastatic renal cell carcinoma